The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAVO.L Regulatory News (AVO)

  • There is currently no data for AVO

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Operator agreement with CircleHealth for Harley St

12 Oct 2015 07:00

RNS Number : 8892B
Advanced Oncotherapy PLC
12 October 2015
 

12 October 2015

ADVANCED ONCOTHERAPY PLC

("Advanced Oncotherapy" or the "Company")

 

Operator agreement with CircleHealth for Harley St site

 

Advanced Oncotherapy (AIM: AVO), the developer of next-generation proton therapy systems for cancer treatment, announces that it has signed a joint venture agreement with CircleHealth ("Circle") to operate the Company's proton beam cancer therapy centre in Harley Street.

 

Circle, owned by AIM-listed Circle Holdings plc (AIM: CIRC) which is an employee co-owned company, runs hospitals and healthcare across the UK. It has nearly 2,000 partners, working across four UK sites.

 

Under the terms of the agreement, Advanced Oncotherapy and Circle will jointly own a newly formed company into which funding of £6 million will be provided in equal portions by the parties and will cover, inter alia, pre-opening costs and working capital. The arrangement, together with further definitive agreements to be finalised in the coming months, would combine Circle's clinician-led operating model with Advanced Oncotherapy's next-generation proton therapy systems for cancer treatment. Once the centre commences operation the equity in the operating company will be owned as to 50.1% by Circle and the remaining 49.9% by Advanced Oncotherapy.

 

The Harley Street facility will house the UK's first high energy proton beam cancer therapy centre. Circle Health will take responsibility for all operational and clinical matters at the facility as well as the additional procurement, fit-out and facility testing requirements needed for full commissioning and beyond the testing required during the technical development of the system. Circle Health will also take responsibility for insurance provision for the centre. Advanced Oncotherapy will take responsibility for all technical matters. A number of proposals from international financial institutions concerning the provision of vendor finance for the LIGHT technology in Harley Street are being considered.

 

The LIGHT (short for Linac Image Guided Hadron Technology) system, is a proprietary proton accelerator that will offer healthcare providers affordable proton therapy systems to treat cancer using a technology that in many instances can produce better health outcomes and lower treatment related side effects. The LIGHT system achieves the required energy levels found in legacy proton therapy machines but in a unit that is a fraction of the size and significantly lower in cost. The compact configuration of the LIGHT system lends itself perfectly to the installation of this technology in such central city locations, and the Harley Street site will house London's first ever proton therapy unit.

 

The Company is also in discussions with Circle surrounding an agreement to supply its LIGHT system alongside CircleHealth's planned new-build independent hospital in Edgbaston, Birmingham.

 

Steve Melton, Chief Executive of CircleHealth, said:

 

"This is great news for patients, for Circle and for Advanced Oncotherapy. Advanced Oncotherapy is creating a genuinely revolutionary technology, at the cutting edge of cancer treatment. We're delighted to be working with them. When completed this deal means the expansion of Circle into London - giving us a presence in one of the world's greatest medical centres - and into cancer care, where there is huge potential for new technologies and exciting new treatments. For Circle, this is a clear signal of our intention to grow and expand, by combining our experience in operations with other organisations' specialist skills."

 

Commenting, Sanjeev Pandya, CEO of Advanced Oncotherapy, said:

 

"Circle Health has a great record for providing innovative healthcare delivery and are the ideal candidate to operate our flagship Harley Street site. Whilst we expect our ongoing business model to focus on Advanced Oncotherapy as a manufacturer of cutting edge proton therapy systems, we felt it was crucial, given the strategic importance of our first site in Harley Street, to have a vested interest in the ongoing operational success of our facility. Working alongside Circle Health, we expect it to transform the UK's approach to cancer radiotherapy treatment."

 

Advanced Oncotherapy Plc

www.avoplc.com

Sanjeev Pandya, CEO

Tel: +44 (0)20 3617 8728

Nicolas Serandour, CFO

Westhouse Securities (Nomad & Joint Broker)

Antonio Bossi / David Coaten

Tel: +44 (0)20 7601 6100

Beaufort Securities (Joint Broker)

Jon Levinson / Zoe Alexander

Tel: +44 (0)20 7382 8300

Walbrook PR (Financial PR & IR)

Tel: +44 (0)20 7933 8780 or avo@walbrookpr.com

Paul McManus / Anna Dunphy

Mob: +44 (0)7980 541 893 / Mob: +44 (0)7876 741 001

 

 

About Advanced Oncotherapy Plc www.avoplc.com

 

Advanced Oncotherapy's team "ADAM" based in Geneva focuses on the development of a proprietary proton accelerator called Linac Image Guided Hadron Technology (LIGHT). LIGHT accelerates protons to the energy levels achieved in legacy machines but in a unit that is a fraction of the size and significantly lower in cost. This compact configuration delivers proton beams in a way that facilitates a greater precision and electronic control which is not achievable with older technologies.

 

Advanced Oncotherapy is a provider of particle therapy with protons that harnesses the best in modern technology. As a result, Advanced Oncotherapy will offer healthcare providers affordable systems that will enable them to treat cancer with an innovative technology as well as better health outcomes and lower treatment related side effects.

 

The Company has signed a purchase agreement with Sinophi Healthcare Limited for one LIGHT proton therapy system to be installed in a hospital in China and has further Letters of Intent from other healthcare providers.

 

Advanced Oncotherapy continually monitors the market for any emerging improvements in delivering proton therapy and actively seeks working relationships with providers of these innovative technologies. Through these relationships, the Company will remain the prime provider of an innovative and cost-effective system for particle therapy with protons.

 

 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
JVEMBBTTMBTBTAA
Date   Source Headline
4th Jul 20189:00 amRNSPrice Monitoring Extension
2nd Jul 20187:00 amRNSDirectorate Changes
27th Jun 20187:00 amRNSFinal Results
31st May 20187:00 amRNSUpdate on financing
29th May 20187:00 amRNSTechnological update
11th May 20184:35 pmRNSPrice Monitoring Extension
11th May 20187:00 amRNSUpdate on Distribution Agreement Payment
8th May 20187:00 amRNSUK assembly and testing site agreement
26th Apr 20181:50 pmRNSGPSL Research on Advanced Oncotherapy Plc
5th Apr 20187:00 amRNSHolding(s) in Company
3rd Apr 20189:43 amRNSUpdate on Distribution Agreement
12th Mar 20187:15 amRNSHardman & Co Research: Confidence greatly boosted
23rd Feb 20184:05 pmRNSHolding(s) in Company
16th Feb 20187:00 amRNSCompletion of the Subscription Agreement
23rd Jan 201811:48 amRNSResult of Meeting
12th Jan 20187:00 amRNSDirector dealing
28th Dec 20177:01 amRNSNotice of GM
28th Dec 20177:00 amRNSTechnological update
22nd Dec 201711:24 amRNSHolding(s) in Company
13th Dec 20174:25 pmRNSHolding(s) in Company
11th Dec 20172:02 pmRNSHardman Res.: Distribution deal & capital increase
7th Dec 20177:00 amRNSDistribution agreement and Equity Investments
29th Sep 20177:00 amRNSHalf-year Report
4th Sep 20177:00 amRNSTechnological update
1st Aug 20177:00 amRNSDirector Dealing
31st Jul 20177:00 amRNSTechnological milestones update - CCL units
19th Jul 20173:56 pmRNSResult of AGM
19th Jul 201710:16 amRNSFinancing facility by significant shareholders
5th Jul 20177:00 amRNSVideo and update on progress at Harley Street
26th Jun 20177:00 amRNSFinal Results
21st Jun 20177:00 amRNSConversion of Convertible Loan Notes
14th Jun 20177:00 amRNSAppointment of Senior VP of Medical Physics
13th Jun 20177:00 amRNSAdditional financing agreement and new appointment
12th Jun 20177:00 amRNSTechnological milestones update
5th Jun 20172:45 pmRNSUpdate on Bracknor financing
31st May 20174:41 pmRNSHolding(s) in Company
30th May 20177:00 amRNSHarley Street construction update
26th May 20176:23 pmRNSConversion of Convertible Loan Notes
26th May 20177:00 amRNSUpdate on Bracknor financing
24th May 20177:13 amRNSConversion of convertible loan notes
23rd May 201712:01 pmRNSHolding(s) in Company
18th May 20177:31 amRNSConversion of convertible loan notes
16th May 20179:02 amRNSConversion of loan notes
15th May 20171:01 pmRNSDirector Dealing
11th May 20177:00 amRNSDirector Dealing
8th May 20177:00 amRNSIssue of Equity & Director Shareholding
4th May 20177:05 amRNSHolding(s) in Company
3rd May 20171:29 pmRNSHolding(s) in Company
28th Apr 20177:00 amRNSUpdate on Bracknor financing
26th Apr 201711:18 amRNSDirector Dealing

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.